Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Clinical & Experimental Metastasis
Published in: Clinical & Experimental Metastasis 5/2012

01-06-2012 | Research Paper

Silencing of skeletal metastasis-associated genes impairs migration of breast cancer cells and reduces osteolytic bone lesions

Authors: Christina Reufsteck, Rinat Lifshitz-Shovali, Michael Zepp, Tobias Bäuerle, Dieter Kübler, Gershon Golomb, Martin R. Berger

Published in: Clinical & Experimental Metastasis | Issue 5/2012

Login to get access

Abstract

Bone sialoprotein (BSP) and osteopontin (OPN) are important factors in the metastasis of breast cancer, which were examined as targets for antineoplastic therapy by siRNA. In addition, the effect of gene silencing on their transcription factor Runx2 and their interaction partners integrin β3 and matrix metalloproteinase 2 was studied. The effect of siRNAs directed against these genes was assessed by monitoring expression levels followed by functional assays in cell culture as well as skeletal metastases caused by human MDA-MB-231luc breast cancer cells in nude rats. Upon silencing of the targets, cell migration was profoundly impaired (p < 0.001 for BSP-siRNA), but the impact on proliferation was low. Systemic administration by osmotic mini-pumps of BSP-siRNA but not OPN-siRNA decreased osteolytic lesions (p = 0.067). Extraosseous tumour growth was not affected. As an alternative approach, non-viral, polymeric based formulations of siRNAs in nanoparticles (NP) were developed. Locoregional administration of the two siRNAs targeting OPN and BSP encapsulated in these biodegradable NP reduced skeletal lesions even more efficiently (p = 0.03). Compared to systemic administration, this treatment caused not only a more pronounced anti-osteolytic effect at a 25-fold lower total siRNA dose, but also had a slight reducing effect on tumour incidence (p = 0.095). In conclusion, the siRNA treatment had a small effect on cellular proliferation but a significant efficacy against migration of and osteolysis induced by MDA-MB-231 cells. Our data underline that siRNA mediated knockdown is a powerful tool for identifying targets for pharmacological intervention. In addition, encapsulation of siRNA into biodegradable NP is a strategy, which promises well for using siRNA.
Appendix
Available only for authorised users
Literature
1.
Weinberg RA (2006) The biology of cancer. Garland Science, Oxford
2.
Berenson JR (2001) Zoledronic acid in cancer patients with bone metastases: results of Phase I and II trials. Semin Oncol 28(2 Suppl 6):25–34PubMedCrossRef
3.
4.
5.
Slamon DJ, Leyland-Jones B, Shak S et al (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. New Engl J Med 344(11):783–792PubMedCrossRef
6.
Theriault RL, Lipton A, Hortobagyi GN et al (1999) Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial. Protocol 18 Aredia Breast Cancer Study Group. J Clin Oncol 17(3):846–854PubMed
7.
Bos PD, Zhang XH, Nadal C et al (2009) Genes that mediate breast cancer metastasis to the brain. Nature 459(7249):1005–1009PubMedCrossRef
8.
Kang Y, Siegel PM, Shu W et al (2003) A multigenic program mediating breast cancer metastasis to bone. Cancer Cell 3(6):537–549PubMedCrossRef
9.
Heinegard D, Oldberg A (1989) Structure and biology of cartilage and bone matrix noncollagenous macromolecules. FASEB J 3(9):2042–2051PubMed
10.
Fisher LW, Whitson SW, Avioli LV et al (1983) Matrix sialoprotein of developing bone. J Biol Chem 258(20):12723–12727PubMed
11.
Fisher LW, Torchia DA, Fohr B et al (2001) Flexible structures of SIBLING proteins, bone sialoprotein, and osteopontin. Biochem Biophys Res Commun 280(2):460–465PubMedCrossRef
12.
Noda M, Rodan GA (1989) Type beta transforming growth factor regulates expression of genes encoding bone matrix proteins. Connect Tissue Res 21(1–4):71–75PubMedCrossRef
13.
Ogata Y, Yamauchi M, Kim RH et al (1995) Glucocorticoid regulation of bone sialoprotein (BSP) gene expression. Identification of a glucocorticoid response element in the bone sialoprotein gene promoter. Eur J Biochem/FEBS 230(1):183–192CrossRef
14.
Pratap J, Lian JB, Javed A et al (2006) Regulatory roles of Runx2 in metastatic tumor and cancer cell interactions with bone. Cancer Metastasis Rev 25(4):589–600PubMedCrossRef
15.
Byzova TV, Kim W, Midura RJ et al (2000) Activation of integrin alpha(V)beta(3) regulates cell adhesion and migration to bone sialoprotein. Exp Cell Res 254(2):299–308PubMedCrossRef
16.
Das R, Mahabeleshwar GH, Kundu GC (2003) Osteopontin stimulates cell motility and nuclear factor kappaB-mediated secretion of urokinase type plasminogen activator through phosphatidylinositol 3-kinase/Akt signaling pathways in breast cancer cells. J Biol Chem 278(31):28593–28606PubMedCrossRef
17.
DeMali KA, Wennerberg K, Burridge K (2003) Integrin signaling to the actin cytoskeleton. Curr Opin Cell Biol 15(5):572–582PubMedCrossRef
18.
Gordon JA, Sodek J, Hunter GK et al (2009) Bone sialoprotein stimulates focal adhesion-related signaling pathways: role in migration and survival of breast and prostate cancer cells. J Cell Biochem 107(6):1118–1128PubMedCrossRef
19.
Guo W, Giancotti FG (2004) Integrin signalling during tumour progression. Nat Rev Mol Cell Biol 5(10):816–826PubMedCrossRef
20.
Kiosses WB, Shattil SJ, Pampori N et al (2001) Rac recruits high-affinity integrin alphavbeta3 to lamellipodia in endothelial cell migration. Nat Cell Biol 3(3):316–320PubMedCrossRef
21.
Rangaswami H, Bulbule A, Kundu GC (2006) Osteopontin: role in cell signaling and cancer progression. Trends Cell Biol 16(2):79–87PubMedCrossRef
22.
Sharp JA, Waltham M, Williams ED et al (2004) Transfection of MDA-MB-231 human breast carcinoma cells with bone sialoprotein (BSP) stimulates migration and invasion in vitro and growth of primary and secondary tumors in nude mice. Clin Exp Metastasis 21(1):19–29PubMedCrossRef
23.
Bellahcene A, Castronovo V, Ogbureke KU et al (2008) Small integrin-binding ligand N-linked glycoproteins (SIBLINGs): multifunctional proteins in cancer. Nat Rev Cancer 8(3):212–226PubMedCrossRef
24.
Fedarko NS, Jain A, Karadag A et al (2001) Elevated serum bone sialoprotein and osteopontin in colon, breast, prostate, and lung cancer. Clin Cancer Res 7(12):4060–4066PubMed
25.
Bellahcene A, Kroll M, Liebens F et al (1996) Bone sialoprotein expression in primary human breast cancer is associated with bone metastases development. J Bone Miner Res 11(5):665–670PubMedCrossRef
26.
Bellahcene A, Menard S, Bufalino R et al (1996) Expression of bone sialoprotein in primary human breast cancer is associated with poor survival. Int J Cancer 69(4):350–353PubMedCrossRef
27.
Bramwell VH, Doig GS, Tuck AB et al (2006) Serial plasma osteopontin levels have prognostic value in metastatic breast cancer. Clin Cancer Res 12(11 Pt 1):3337–3343PubMedCrossRef
28.
Diel IJ, Solomayer EF, Seibel MJ et al (1999) Serum bone sialoprotein in patients with primary breast cancer is a prognostic marker for subsequent bone metastasis. Clin Cancer Res 5(12):3914–3919PubMed
29.
Rudland PS, Platt-Higgins A, El-Tanani M et al (2002) Prognostic significance of the metastasis-associated protein osteopontin in human breast cancer. Cancer Res 62(12):3417–3427PubMed
30.
Shevde LA, Das S, Clark DW et al (2010) Osteopontin: an effector and an effect of tumor metastasis. Curr Mol Med 10(1):71–81PubMedCrossRef
31.
Hedley BD, Welch DR, Allan AL et al (2008) Downregulation of osteopontin contributes to metastasis suppression by breast cancer metastasis suppressor 1. Int J Cancer 123(3):526–534PubMedCrossRef
32.
Adwan H, Bauerle T, Najajreh Y et al (2004) Decreased levels of osteopontin and bone sialoprotein II are correlated with reduced proliferation, colony formation, and migration of GFP-MDA-MB-231 cells. Int J Oncol 24(5):1235–1244PubMed
33.
Adwan H, Bauerle TJ, Berger MR (2004) Downregulation of osteopontin and bone sialoprotein II is related to reduced colony formation and metastasis formation of MDA-MB-231 human breast cancer cells. Cancer Gene Ther 11(2):109–120PubMedCrossRef
34.
Uccello M, Malaguarnera G, Vacante M et al (2011) Serum bone sialoprotein levels and bone metastases. J Cancer Res Ther 7(2):115–119PubMedCrossRef
35.
Bauerle T, Adwan H, Kiessling F et al (2005) Characterization of a rat model with site-specific bone metastasis induced by MDA-MB-231 breast cancer cells and its application to the effects of an antibody against bone sialoprotein. Int J Cancer 115(2):177–186PubMedCrossRef
36.
Weber GF (2001) The metastasis gene osteopontin: a candidate target for cancer therapy. Biochim Biophys Acta 1552(2):61–85PubMed
37.
Elazar V, Adwan H, Bauerle T et al (2010) Sustained delivery and efficacy of polymeric nanoparticles containing osteopontin and bone sialoprotein antisenses in rats with breast cancer bone metastasis. Int J Cancer 126(7):1749–1760PubMed
38.
Dias N, Stein CA (2002) Antisense oligonucleotides: basic concepts and mechanisms. Mol Cancer Ther 1(5):347–355PubMed
39.
Cohen-Sacks H, Najajreh Y, Tchaikovski V et al (2002) Novel PDGFbetaR antisense encapsulated in polymeric nanospheres for the treatment of restenosis. Gene Ther 9(23):1607–1616PubMedCrossRef
40.
Elazar V, Adwan H, Rohekar K et al (2010) Biodistribution of antisense nanoparticles in mammary carcinoma rat model. Drug Deliv 17(6):408–418PubMedCrossRef
41.
Park JS, Na K, Woo DG et al (2010) Non-viral gene delivery of DNA polyplexed with nanoparticles transfected into human mesenchymal stem cells. Biomaterials 31(1):124–132PubMedCrossRef
42.
Senger DR, Perruzzi CA (1996) Cell migration promoted by a potent GRGDS-containing thrombin-cleavage fragment of osteopontin. Biochim Biophys Acta 1314(1–2):13–24PubMedCrossRef
43.
Dahlgren C, Zhang HY, Du Q et al (2008) Analysis of siRNA specificity on targets with double-nucleotide mismatches. Nucleic Acids Res 36(9):e53PubMedCrossRef
44.
He J, Zhang JF, Yi C et al (2010) miRNA-mediated functional changes through co-regulating function related genes. PLoS ONE 5(10):e13558PubMedCrossRef
45.
Soldani C, Scovassi AI (2002) Poly(ADP-ribose) polymerase-1 cleavage during apoptosis: an update. Apoptosis 7(4):321–328PubMedCrossRef
46.
Gross A, McDonnell JM, Korsmeyer SJ (1999) BCL-2 family members and the mitochondria in apoptosis. Genes Dev 13(15):1899–1911PubMedCrossRef
47.
Duffy MJ, Maguire TM, Hill A et al (2000) Metalloproteinases: role in breast carcinogenesis, invasion and metastasis. Breast Cancer Res 2(4):252–257PubMedCrossRef
48.
Bauerle T, Peterschmitt J, Hilbig H et al (2006) Treatment of bone metastasis induced by MDA-MB-231 breast cancer cells with an antibody against bone sialoprotein. Int J Oncol 28(3):573–583PubMed
49.
Peterschmitt J, Bauerle T, Berger MR (2007) Effect of zoledronic acid and an antibody against bone sialoprotein II on MDA-MB-231(GFP) breast cancer cells in vitro and on osteolytic lesions induced in vivo by this cell line in nude rats. Clin Exp Metastasis 24(6):449–459PubMedCrossRef
50.
Bauerle T, Hilbig H, Bartling S et al (2008) Bevacizumab inhibits breast cancer-induced osteolysis, surrounding soft tissue metastasis, and angiogenesis in rats as visualized by VCT and MRI. Neoplasia 10(5):511–520PubMed
51.
Shevde LA, Samant RS, Paik JC et al (2006) Osteopontin knockdown suppresses tumorigenicity of human metastatic breast carcinoma, MDA-MB-435. Clin Exp Metastasis 23(2):123–133PubMedCrossRef
52.
Davis ME, Zuckerman JE, Choi CH et al (2010) Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature 464(7291):1067–1070PubMedCrossRef
53.
Lundberg BB (1997) Ether lipids enhance the cytotoxic effect of teniposide and paclitaxel in liposomes against leukaemic cells in culture. Anticancer Drug Des 12(6):503–513PubMed
Metadata
Title
Silencing of skeletal metastasis-associated genes impairs migration of breast cancer cells and reduces osteolytic bone lesions
Authors
Christina Reufsteck
Rinat Lifshitz-Shovali
Michael Zepp
Tobias Bäuerle
Dieter Kübler
Gershon Golomb
Martin R. Berger
Publication date
01-06-2012
Publisher
Springer Netherlands
Published in
Clinical & Experimental Metastasis / Issue 5/2012
Print ISSN: 0262-0898
Electronic ISSN: 1573-7276
DOI
https://doi.org/10.1007/s10585-012-9462-8

Other articles of this Issue 5/2012

Clinical & Experimental Metastasis 5/2012 Go to the issue

Research Paper

Paracrine signalling in colorectal liver metastases involving tumor cell-derived PDGF-C and hepatic stellate cell-derived PAK-2

Research Paper

The over-expression of cell migratory genes in alveolar rhabdomyosarcoma could contribute to metastatic spread

Research Paper

Insidious role of nitric oxide in migration/invasion of colon cancer cells by upregulating MMP-2/9 via activation of cGMP-PKG-ERK signaling pathways

Research Paper

Luminal breast cancer metastasis is dependent on estrogen signaling

Research Paper

Elastin-derived peptides increase invasive capacities of lung cancer cells by post-transcriptional regulation of MMP-2 and uPA

Research Paper

Inhibitory effect of non-anticoagulant heparin (S-NACH) on pancreatic cancer cell adhesion and metastasis in human umbilical cord vessel segment and in mouse model
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits